Hologic, Inc. (NASDAQ:HOLX - Free Report) - Leerink Partnrs cut their Q1 2025 earnings estimates for Hologic in a research report issued on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical equipment provider will post earnings of $1.02 per share for the quarter, down from their previous forecast of $1.03. The consensus estimate for Hologic's current full-year earnings is $4.09 per share. Leerink Partnrs also issued estimates for Hologic's Q3 2025 earnings at $1.08 EPS and FY2026 earnings at $4.74 EPS.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. During the same period in the prior year, the company earned $0.89 EPS. The firm's revenue was up 4.5% on a year-over-year basis.
HOLX has been the topic of several other reports. Citigroup lowered Hologic from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research note on Tuesday, October 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, October 15th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a report on Tuesday. Finally, UBS Group raised their target price on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $89.25.
Get Our Latest Report on Hologic
Shares of NASDAQ HOLX opened at $78.80 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic has a 1-year low of $66.93 and a 1-year high of $84.67. The company has a market capitalization of $18.30 billion, a price-to-earnings ratio of 26.80, a PEG ratio of 2.98 and a beta of 0.98. The business has a 50-day moving average of $81.06 and a 200-day moving average of $78.08.
Several large investors have recently added to or reduced their stakes in HOLX. Norden Group LLC raised its holdings in Hologic by 44.0% during the first quarter. Norden Group LLC now owns 5,480 shares of the medical equipment provider's stock valued at $427,000 after buying an additional 1,675 shares in the last quarter. Fidelis Capital Partners LLC acquired a new position in shares of Hologic during the 1st quarter valued at about $63,000. Daiwa Securities Group Inc. lifted its holdings in Hologic by 0.8% in the 1st quarter. Daiwa Securities Group Inc. now owns 36,160 shares of the medical equipment provider's stock worth $2,819,000 after purchasing an additional 270 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in Hologic by 22.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 40,286 shares of the medical equipment provider's stock worth $3,141,000 after purchasing an additional 7,432 shares during the last quarter. Finally, Central Pacific Bank Trust Division bought a new stake in Hologic during the first quarter worth approximately $77,000. 94.73% of the stock is owned by institutional investors.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.